dc.contributor.author | Johnson, L | |
dc.contributor.author | O'Donoghue, JM | |
dc.contributor.author | McLean, N | |
dc.contributor.author | Turton, P | |
dc.contributor.author | Khan, AA | |
dc.contributor.author | Turner, SD | |
dc.contributor.author | Lennard, A | |
dc.contributor.author | Collis, N | |
dc.contributor.author | Butterworth, M | |
dc.contributor.author | Gui, G | |
dc.contributor.author | Bristol, J | |
dc.contributor.author | Hurren, J | |
dc.contributor.author | Smith, S | |
dc.contributor.author | Grover, K | |
dc.contributor.author | Spyrou, G | |
dc.contributor.author | Krupa, K | |
dc.contributor.author | Azmy, IA | |
dc.contributor.author | Young, IE | |
dc.contributor.author | Staiano, JJ | |
dc.contributor.author | Khalil, H | |
dc.contributor.author | MacNeill, FA | |
dc.date.accessioned | 2018-04-27T11:36:59Z | |
dc.date.issued | 2017-08 | |
dc.identifier.citation | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, 43 (8), pp. 1393 - 1401 | |
dc.identifier.issn | 0748-7983 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1658 | |
dc.identifier.eissn | 1532-2157 | |
dc.identifier.doi | 10.1016/j.ejso.2017.05.004 | |
dc.description.abstract | Background Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent effusion and/or mass. Tumours exhibit CD30 expression and are negative for Anaplastic Lymphoma Kinase (ALK). We report the multi-disciplinary management of the UK series and how the stage of disease may be used to stratify treatment.Methods Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres throughout the UK. Data on breast implant surgeries, clinical features, treatment and follow-up were available for 18 patients.Results The mean lead-time from initial implant insertion to diagnosis was 10 years (range: 3-16). All cases were observed in patients with textured breast implants or expanders. Fifteen patients with breast implants presented with stage I disease (capsule confined), and were treated with implant removal and capsulectomy. One patient received adjuvant chest-wall radiotherapy. Three patients presented with extra-capsular masses (stage IIA). In addition to explantation, capsulectomy and excision of the mass, all patients received neo-/adjuvant chemotherapy with CHOP as first line. One patient progressed on CHOP but achieved pathological complete response (pCR) with Brentuximab Vedotin. After a mean follow-up of 23 months (range: 1-56) all patients reported here remain disease-free.Discussion BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required for more invasive disease and our experience has shown the efficacy of Brentuximab as a second line treatment. | |
dc.format | Print-Electronic | |
dc.format.extent | 1393 - 1401 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Neoplasm Staging | |
dc.subject | Treatment Outcome | |
dc.subject | Combined Modality Therapy | |
dc.subject | Device Removal | |
dc.subject | Breast Implants | |
dc.subject | Informed Consent | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Lymphoma, Large-Cell, Anaplastic | |
dc.subject | United Kingdom | |
dc.title | Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-05-08 | |
rioxxterms.versionofrecord | 10.1016/j.ejso.2017.05.004 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-08 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | |
pubs.issue | 8 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 43 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Targeted Therapy | en_US |
dc.contributor.icrauthor | Khan, Aadil | en |